Home › Multiple Myeloma › Iowa › Cedar Rapids
Multiple Myeloma clinical trials in Cedar Rapids, IA
15 studies for Multiple Myeloma are looking for participants at sites in and around Cedar Rapids (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- University of Iowa Hospital and Clinics, Iowa City · 25 mi away
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
RecruitingPhase 1
- Research Site, Iowa City · 25 mi away
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi away
Collection of Tissue Samples for Cancer Research
RecruitingObservational study
- University of Iowa, Iowa City · 25 mi away
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- University of Iowa, Iowa City · 25 mi away
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, Iowa City · 25 mi away
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Iowa City · 25 mi away
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- University of Iowa, Iowa City · 25 mi away
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Physicians' Clinic of Iowa PC, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RecruitingPhase 2
- University of Iowa, Iowa City · 25 mi away
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
RecruitingPhase 1
- University of Iowa Health Care, Iowa City · 25 mi away
Activity Levels in Bone Marrow Transplant Patients
RecruitingObservational study
- University of Iowa, Iowa City · 25 mi away
Sleep Apnea in Patients With MGUS and MM
RecruitingObservational study
- University of Iowa, Iowa City · 25 mi away
Limited-duration Teclistamab
RecruitingPhase 2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi away
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO26 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- St. Louis, MO23 studies
- Rochester, MN23 studies
- Washington, DC22 studies
Other studies in Cedar Rapids
- Non-Small Cell Lung Cancer20 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia16 studies
- Cancer (all types)16 studies
- Lung Cancer14 studies
- Colorectal Cancer13 studies
- Prostate Cancer12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Melanoma10 studies
- Stroke10 studies
- Endometrial Cancer10 studies
- Blood Cancers9 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.